



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Futuximab

<b>Cat. No.:</b>	HY-P99628
<b>CAS No.:</b>	1310460-85-5
<b>Target:</b>	EGFR
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity <sup>[1]</sup> .	
<b>In Vitro</b>	Futuximab (20 µg/mL; 24-48 h) induces EGFR variant III (EGFRvIII) internalization and slightly reduces EGFRvIII levels in NR6M cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis <sup>[1]</sup>	
	Cell Line:	NR6M cells
	Concentration:	20 µg/mL
	Incubation Time:	24 h or 48 h
	Result:	Slightly reduced EGFRvIII levels in NR6M cells.
<b>In Vivo</b>	Futuximab (50 mg/kg; i.p.; twice weekly; for 5 weeks) shows anti-tumor activity in EGFRwt expressing xenograft model <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Balb/c nu/nu mice injected with EGFRwt (D08-0308MG) patient-derived glioblastoma xenografts (PDX) <sup>[1]</sup>
	Dosage:	50 mg/kg
	Administration:	i.p.; twice weekly; for 5 weeks
	Result:	Inhibited tumor growth in EGFRwt expressing xenograft model.

### REFERENCES

[1]. Stephen T Keir, et al. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. J Neurooncol. 2018 Jul;138(3):489-498.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA